Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
4.260
-0.230 (-5.12%)
At close: Dec 20, 2024, 4:00 PM
4.310
+0.050 (1.17%)
After-hours: Dec 20, 2024, 7:43 PM EST
Cardiff Oncology Revenue
Cardiff Oncology had revenue of $165.00K in the quarter ending September 30, 2024, with 17.02% growth. This brings the company's revenue in the last twelve months to $688.00K, up 49.57% year-over-year. In the year 2023, Cardiff Oncology had annual revenue of $488.00K with 26.42% growth.
Revenue (ttm)
$688.00K
Revenue Growth
+49.57%
P/S Ratio
280.28
Revenue / Employee
$21,500
Employees
32
Market Cap
217.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
Dec 31, 2019 | 244.63K | -133.69K | -35.34% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 370.02M |
Aurora Cannabis | 219.84M |
Heron Therapeutics | 137.74M |
Fulcrum Therapeutics | 80.87M |
Pulmonx | 79.30M |
Electromed | 57.06M |
BGM Group | 29.87M |
Ocugen | 4.70M |
CRDF News
- 7 days ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 9 days ago - Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning - Seeking Alpha
- 11 days ago - Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer - Seeking Alpha
- 11 days ago - Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering - GlobeNewsWire
- 11 days ago - Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC - GlobeNewsWire
- 2 months ago - Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market - Seeking Alpha
- 4 months ago - Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point - Seeking Alpha